Godavari Drugs Ltd (GODAVARI) — shareholding pattern, promoter holding, financials and share price
About Godavari Drugs Ltd (GODAVARI)
Godavari Drugs Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as GODAVARI and on the BSE under scrip code 530317. Its ISIN is INE362C01012.
Incorporated in 1987, Godavari Drugs Ltd manufactures and sale of Active Pharmaceutical Ingredients and their intermediates [1]
Godavari Drugs Limited manufactures Active Pharmaceutical Ingredients (API) and drug intermediates with a focus on Sulphamethoxazole (SMX), a commonly used antibiotic with robust export demand.
The company has strategically expanded its SMX capacity and integrated backward into producing important drug intermediates, enhancing value addition and operational efficiency.
Listed peers in Pharmaceuticals: Bal Pharma Ltd, Lactose (India) Ltd, Tyche Industries Ltd, Pharmaids Pharmaceuticals Ltd, Krebs Biochemicals & Industries Ltd, Sotac Pharmaceuticals Ltd.
Valuation & Returns
10 Jul 2026At ₹123 a share on 10 Jul 2026, Godavari Drugs Ltd (GODAVARI) was valued at a price-to-earnings ratio of 30.46x against an industry P/E of 36.41x and a price-to-book of 2.87x on a book value of ₹42.8 per share as of Mar 2025. Solomo computes return on equity of 9.44% and return on capital employed of 8.61% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 30.46x
- Industry P/E
- 36.41x
- P/B
- 2.87x
- EPS (TTM)
- ₹4.04
- Book value / share
- ₹42.8
- ROE
- 9.44%
- ROCE
- 8.61%
- ROA
- 2.86%
- Debt / equity
- 1.42x
- Dividend yield
- 0%
- EBITDA margin
- 10.85%
- 52-week range
- ₹69.7 – ₹135.25
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Godavari Drugs Ltd (GODAVARI) reported revenue of ₹106 crore, net profit of ₹4 crore and earnings per share of ₹4.04. That compares with revenue of ₹113 crore and net profit of ₹4 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹33.16 crore and net profit ₹1.29 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 161 | 160 | 157 | 113 | 106 |
| Net profit (₹ cr) | 5 | 4 | 6 | 4 | 4 |
| EPS (₹) | 6.97 | 5.03 | 7.37 | 5.82 | 4.04 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 5.32% | 3.44% | -11.06% | -27.67% |
| Profit growth | 13.96% | 16.96% | -5.83% | -21.08% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 40.23% of Godavari Drugs Ltd (GODAVARI) (unchanged from the previous quarter) and domestic institutional investors (DII) hold 2.74%. Promoters have pledged 0.2% of their holding. Market capitalisation was ₹125 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: HUF 2.38%, SACHIN KASERA 2.22%, SURYATEJ ADVISORS LLP 2.22%, HIGHCRESTT GLOBAL COMPANY LTD 1.97%, KETAN V THAKKAR 1.66%, UMESH KUMAR GUPTA 1.4%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 40.23% | 0.2% | - | 2.74% | 59.77% |
| Mar 2026 | 40.23% | 0.2% | - | 2.47% | 59.77% |
| Dec 2025 | 52.61% | 0.2% | - | 0.5% | 47.39% |
| Sep 2025 | 52.61% | 0.2% | - | 0.5% | 47.39% |
| Jun 2025 | 52.63% | 0.3% | - | 0.5% | 47.37% |
| Mar 2025 | 52.63% | 0.3% | - | 0.5% | 47.37% |
| Dec 2024 | 52.63% | 0.3% | - | 0.5% | 47.37% |
| Sep 2024 | 52.63% | 0.3% | - | 0.5% | 47.37% |